GPT and Hypertension: A phase I study of cabozantinib in Japanese patients with NSCLC demonstrated that 70% (16/23) of patients experienced ≥ grade 3 AEs, and the most common AEs included palmar-plantar erythrodysesthesia (100%), increased alanine aminotransferase (95%), increased aspartate aminotransferase (95%), hypertension (87%), and diarrhea (78%) (41).